Orphan medicines: special treatment required?: case study 2: Diacomit and severe myoclonic epilepsy in infancy

Document type
Case study
Corporate author(s)
2020health (Think tank)
Date of publication
1 November 2012
Health Services
Social welfare
Material type

Download (124KB )

This case study on the drug Diacomit and treatment of severe myoclonic epilepsy in infancy accompanies a report that examines the evidence to see if there are ways of improving decision making on treatments for people with rare diseases in the NHS. Diacomit (stiripentol) marketed by Laboratoires Biocodex, is an antiepileptic, or anticonvulsant, medicine. It has been shown in clinical trials to be useful as an add-on to clobazam and valproate (and other antiepileptic medicines) for children with a very rare type of epilepsy called severe myoclonic epilepsy in infancy (SMEI), also known as Dravet’s syndrome. Together treatments can help reduce the number of seizures.

Diacomit was awarded orphan drug status for its use in SMEI in 2001, reflecting the small number of patients with SMEI. Marketing approval followed in 2007, with Diacomit being authorised by European Medicines Agency for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonicclonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI or Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate. Diacomet is perceived as fulfilling a treatment gap when previous treatments have been unsuccessful.

Related to 2020health

The fear of finding out: identifying psychological barriers to diagnosis in the UK.

This report uses literature data, observations and discussions to frame a new approach to understanding the nature and implications of health-system avoidance by individuals who choose to remain ignorant

Health technologies: are older people interested?

This report finds that the over 65s made up 17% of the population in 2010, up from 15% in 1985, with projections indicating a rise to 23% by 2035.Exponential growth of an aging population indicates

Foresight Project report: a discussion of the potential impact of

This report by the Foresight Project aims to ensure that the optical sector is better equipped to understand directions in  technology, ocular medical developments and demographics in the years up to 2030.

Fat chance? Exploring the evidence on who becomes obese

Current political, economic and social discourse on obesity in the UK illuminates the great complexities and myriad socio-economic considerations that inform people’s health, diets, and health seeking

More items related to this publisher